Mucosal bacterial immunotherapy with MV130 highly reduces the need of tonsillectomy in adults with recurrent tonsillitis

Luis-Amando García González, Federico Arrutia Díez, Luis-Amando García González, Federico Arrutia Díez

Abstract

Recurrent tonsillitis in adults is a common ENT disease. The current standard treatment is tonsillectomy. However, continuous prophylaxis with antibiotics has been prescribed in order to avoid tonsillectomy. The objective was to evaluate if the bacterial immunotherapy (Bactek MV130) together with the prophylactic antibiotic therapy can produce clinical improvement and to avoid the tonsillectomy. Material and methods: The medical records of 88 patients with recurrent tonsillitis were reviewed. Sixty-six were treated during 3 months with a course of antibiotics and 22 received, in addition to the antibiotics, immunotherapy with Bactek MV130 during this Globally, 53 (60%) patients had clinical improvement and 35 were tonsillectomized. In the The group of patients who received only antibiotic, 35 (53%) avoided tonsillectomy and 31 (47%) did not. In the group that, in addition to antibiotics, were treated with Bactek MV130, 18 patients (82%) experi- enced clinical improvement avoiding tonsillectomy and 4 (18%) didn't improve and the tonsils were surgically removed. The difference between both groups was significant (P = 0.023).he results obtained in this evaluation support this combined treatment as an effective strategy to reduce the need of tonsillectomy.

Keywords: Recurrent tonsillitis; infectious disease; oral mucosal immunotherapy; tonsillectomy.

Figures

Figure 1.
Figure 1.
Flow chart of the study.

References

    1. El Hennawi DED, Geneid A, Zaher S, Ahmed MR.. Management of recurrent tonsillitis in children. Am J Otolaryngol. 2017;38(4):371–74. doi:10.1016/j.amjoto.2017.03.001.
    1. Deutsch ES. Tonsillectomy and adenoidectomy. Changing indications. Pediatr Clin North Am. 1996;43:1319–38.
    1. Hoddeson EK, Gourin CG. Adult tonsillectomy: current indications and outcomes. Otolaryngol Head Neck Surg. 2009;140(1):19–22. doi:10.1016/j.otohns.2008.09.023.
    1. Bhattacharyya N, Kepnes LJ. Economic benefit of tonsillectomy in adults with chronic tonsillitis. Ann Otol Rhinol Laryngol. 2002;111(11):983–88. doi:10.1177/000348940211101106.
    1. Magdalena ML, Caragol L, Sole A, Suarez V, Cillero JA, Rodrigo JP. Protocolo específico para el control del dolor postamigdalectomía en los adultos intervenidos en régimen ambulatorio. Acta Otorrinolaringol Esp. 2013;64(3):211–16. doi:10.1016/j.otorri.2012.11.007.
    1. Leong SC, Karkos PD, Papouliakos SM, Apostolidou MT. Unusual complications of tonsillectomy: a systematic review. Am J Otolaryngol. 2007;28(6):419–22. doi:10.1016/j.amjoto.2006.10.016.
    1. Cohen D, Dor M. Morbidity and mortality of post-tonsillectomy bleeding: analysis of cases. J Laryngol Otol. 2008;122(1):88–92. doi:10.1017/S0022215107006895.
    1. Bellanti JA, Settipane RA. Bacterial vaccines and the innate immune system: a journey of rediscovery for the allergist-immunologist and all health care providers. Allergy Asthma Proc. 2009;30(Suppl 1):S3–4. doi:10.2500/aap.2009.30.3251.
    1. Del-Rio-Navarro BE, Espinosa-Rosales FJ, Flenady V, Sienra-Monge JL. Cochrane review: immunostimulants for preventing respiratory tract infection in children. Evid Based Child Health. 2012;7(2):629–717. doi:10.1002/ebch.1833.
    1. Alecsandru D, Valor L, Sanchez-Ramon S, Gil J, Carbone J, Navarro J, Rodríguez JJ, Rodríguez-Sainz C, Fernández-Cruz E. Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome. Clin Exp Immunol. 2011;164(1):100–07. doi:10.1111/cei.2011.164.issue-1.
    1. Chaturvedi VN, Methwani A, Chaturvedi P, Narang P. Bacterial flora in chronic tonsillitis. Indian Pediatr. 1989;26:52–56.
    1. Aznabaeva LF, Aref’eva NA, Gumerova MI. Immune reactions of palatine tonsils in the patients with chronic tonsillitis and the possibilities for their immunological rehabilitation with the use of imudon. Vestn Otorinolaringol. 2012;6:67–70.
    1. Bitar MA, Saade R. The role of OM-85 BV (Broncho-Vaxom) in preventing recurrent acute tonsillitis in children. Int J Pediatr Otorhinolaryngol. 2013;77(5):670–73. doi:10.1016/j.ijporl.2013.01.009.
    1. Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature. 2006;440(7085):808–12. doi:10.1038/nature04596.
    1. Blander JM, Sander LE. Beyond pattern recognition: five immune checkpoints for scaling the microbial threat. Nat Rev Immunol. 2012;12(3):215–25. doi:10.1038/nri3167.
    1. Sato S, Nomura F, Kawai T, Takeuchi O, Muhlradt PF, Takeda K, Akira S. Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways. J Immunol. 2000;165(12):7096–101. doi:10.4049/jimmunol.165.12.7096.
    1. Negri DR, Riccomi A, Pinto D, Vendetti S, Rossi A, Cicconi R, Ruggiero P, Del Giudice G, De Magistris MT. Persistence of mucosal and systemic immune responses following sublingual immunization. Vaccine. 2010;28(25):4175–80. doi:10.1016/j.vaccine.2010.04.013.
    1. Cuburu N, Kweon MN, Song JH, Hervouet C, Luci C, Sun JB, Hofman P, Holmgren J, Anjuère F, Czerkinsky C. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine. 2007;25(51):8598–610. doi:10.1016/j.vaccine.2007.09.073.
    1. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2005;11(4 Suppl):S45–53. doi:10.1038/nm1213.
    1. Benito-Villalvilla C, Cirauqui C, Diez-Rivero CM, Casanovas M, Subiza JL, Palomares O. MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17, and IL-10 responses via Syk and MyD88. Mucosal Immunol. 2016;10(4):924–935. doi: 10.1038/mi.2016.112. Epub 2016 Dec 14.
    1. Allam JP, Stojanovski G, Friedrichs N, Peng W, Bieber T, Wenzel J, Novak N. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy. 2008;63(6):720–27. doi:10.1111/j.1398-9995.2007.01611.x.
    1. Servicio_Cántabro_de_Salud 2011. Allergy. 2008 Jun;63(6):720–7. doi: 10.1111/j.1398-9995.2007.01611.x
    1. Sistema_de_Salud_de_Aragón Costes medios sanitarios. 2010.
    1. Cenjor C, García-Rodríguez JA, Ramos A, Cervera J, Tomás M, Asensi F, Cañada JL, Gobernado M, Isasiá T, López-Madroñero C, et al. Patient consent to “antimicrobial treatment of tonsillitis”. Acta Otorrinolaringol Esp. 2003;54:369–83.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅